WASHINGTON, DC—Updated data from the SMART trial show that supra-annular self-expanding valves yield similar clinical outcomes as balloon-expandable valves at 2 years, but with less risk of ...
Medtronic : Data Confirms Superior Valve Performance Of Evolut TAVR System In Small Annulus Patients
(RTTNews) - Medtronic plc (MDT) released the two-year results of the SMall Annuli Randomized To Evolut or SAPIEN (SMART) Trial, international head-to-head comparative trial of transfemoral ...
Medtronic plc MDT recently unveiled two-year Small Annuli Randomized to Evolut or SAPIEN (“SMART”) Trial results at the Cardiovascular Research Technologies (“CRT”) 2025 conference in ...
DurAVR ® THV demonstrated a favorable hemodynamic profile sustained to one-year, with an Effective Orifice Area (EOA) of 2.1 + 0.2 cm 2, a Mean Pressure Gradient (MPG) of 8.6 + 2.6 mmHg and Doppler ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback